ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Comparison of Anti-Thymocyte Globulin and Alemtuzumab as Induction Therapy in Older Kidney Transplant Recipients

M. Chaung, E. Hollinger, M. Brokhof, N. Alvey, L. Lineberger, N. Kenyon

Rush University Medical Center, Chicago, IL

Meeting: 2020 American Transplant Congress

Abstract number: D-001

Keywords: Elderly patients, Immunosuppression, Induction therapy, Kidney transplantation

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session D: Kidney Immunosuppression: Induction Therapy

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Anti-Thymocyte Globulin vs. Alemtuzumab: A Comparison of Long-Term Outcomes among Renal Transplant Recipients
  • Induction Therapy with Depleting Antibodies in Low Immunological Risk Renal Transplant Patients Treated with a Steroid Free Regimen – Comparison of Alemtuzumab vs. Antithymocyte Globulin.

*Purpose: The purpose of this study is to evaluate the safety and efficacy of induction with either anti-thymocyte globulin (ATG) (total dose 5 mg/kg) or alemtuzumab (30 mg) in older kidney transplant recipients.

*Methods: This is a single center, retrospective cohort study at a large academic medical center. Kidney transplant recipients age 65 years and older transplanted between November 1, 2012 and September 1, 2018 who received either ATG or alemtuzumab were included in this study. Patients were excluded if they experienced death prior to discharge, received a prior transplant, or received multi-organ transplantation. Data from both cohorts was compared using Fisher’s exact test and Chi-Square. The primary end-point is biopsy proven acute rejection (BPAR) at 6 months and 12 months post-transplant. Secondary end-points include patient and graft survival, incidence of infection, 30-day readmission rate, and hospital length of stay.

*Results: A total of 115 patients were screened for inclusion and 60 patients were included in this study: 19 received ATG and 41 received alemtuzumab. BPAR at 6 months for ATG and alemtuzumab were 10.5% (2/19) and 2.4% (1/41) respectively, (p=NS). BPAR at 12 months for ATG and alemtuzumab were 10.5% (2/19) and 4.9% (2/41) respectively, (p=NS). The median hospital length of stay for both groups was 4 days and no statistical significance was found for incidence of CMV (cytomegalovirus) infection, BK virus, urinary tract infection, and community acquired pneumonia. Patient and graft survival was greater than 90% in both cohorts (p=NS) and 30-day readmission rates were not statistically significant different between groups.

*Conclusions: The results of this study demonstrate no statistically significant difference in BPAR, incidence of infection, hospital length of stay, patient and graft survival with ATG or alemtuzumab induction in older kidney transplant recipients.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Chaung M, Hollinger E, Brokhof M, Alvey N, Lineberger L, Kenyon N. Comparison of Anti-Thymocyte Globulin and Alemtuzumab as Induction Therapy in Older Kidney Transplant Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/comparison-of-anti-thymocyte-globulin-and-alemtuzumab-as-induction-therapy-in-older-kidney-transplant-recipients/. Accessed February 26, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
      • Left-Sided Donor Nephrectomy Predisposes Living Kidney Donors to Latent Adrenal Insufficiency with Symptoms of Fatigue and Inferior Quality of Life.
      • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.

      Visit Our Partner Sites

      American Transplant Congress (ATC)

      Visit the official site for the American Transplant Congress »

      American Journal of Transplantation

      The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

      American Society of Transplantation (AST)

      An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

      American Society of Transplant Surgeons (ASTS)

      The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

      Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

      Privacy Policy

      loading Cancel
      Post was not sent - check your email addresses!
      Email check failed, please try again
      Sorry, your blog cannot share posts by email.
      This site uses cookies: Find out more.